Corvus Pharmaceuticals is progressing its drug soquelitinib in a phase 3 trial for relapsed/refractory peripheral T-cell lymphoma (r/r PTCL), with key interim analysis expected in early 2027 and final data by the end of 2027. The company is also expanding soquelitinib's use into autoimmune diseases like atopic dermatitis and asthma, anticipating multiple data readouts in 2027. With $202.9 million in cash as of September 2026, Corvus is financially secure through mid-2028 and faces no near-term dilution risk, supporting ongoing development and clinical programs.
Corvus Pharmaceuticals' advancement of soquelitinib is noted alongside a strong health sector performance on Pluang, where 127 of 150 US health stocks rose as of Nov 10, 2026 05:21 WIB. Among these, Immunovant Inc. (IMVT) gained 15.00% with a typical hold time of 6 days and a near-even buy-sell split, while ImmunityBio Inc. (IBRX) dropped 17.20% with 96% buy orders and a 3-day hold time. Arrowhead Pharmaceuticals Inc. (ARWR) declined 14.68% with a typical hold time of 25 days.
The India paints and coatings market is projected to grow from $12.51 billion in 2026 to $21.17 billion by 2032, at a CAGR of 9.14%. Growth is fueled by expanding residential construction, rising demand for decorative repainting, and increased automo...
INVE Technologies has formed a strategic partnership with Trackonomy to integrate Trackonomy's Physical AI platform into INVE's acquired enterprise software products. This collaboration aims to enhance software offerings with real-world operational d...
AmpliTech Group, a company specializing in RF and microwave components for telecom and defense, will announce its third quarter 2026 financial results on November 12, 2026, after market close. The company will host a conference call at 5:00 PM ET the...
Toll Brothers has announced the grand opening of new luxury single-story model homes at Hidden Vista, a gated community in Palm Desert, California, on November 14. These homes offer up to 2,700 sq ft with 3-4 bedrooms, modern open floor plans, and pr...
FocusReactive, a web development agency specializing in Next.js and headless CMS, achieved top rankings across six major industry review platforms in 2026, including Clutch, DesignRush, and The Manifest. The agency was recognized globally for experti...
